Triple-agonist retatrutide delivers major gains in obstructive sleep apnea

Clinical takeaway: Retatrutide produced substantial and sustained improvements in OSA severity among adults with overweight or obesity, highlighting the potential role of intensive weight-loss therapy as a disease-modifying approach to OSA management.

Excess adiposity is a major contributor to OSA, yet durable weight loss is difficult to achieve with lifestyle interventions alone. These findings suggest that substantial pharmacologically induced weight loss may improve OSA severity and increase the likelihood of remission or mild disease.

Researchers evaluated retatrutide in the phase 3 TRIUMPH-1-OSA and TRIUMPH-2-OSA trials, which enrolled 691 adults with overweight or obesity and moderate-to-severe OSA, including participants with and without type 2 diabetes. Most participants had severe OSA at baseline, with mean apnea-hypopnea index (AHI) values of approximately 56 to 59 events per hour.

At week 80, retatrutide reduced AHI by approximately 53% to 57% in participants without diabetes and about 40% in those with type 2 diabetes, compared with reductions of 11% to 13% with placebo. Mean AHI fell by roughly 32 to 34 events per hour in TRIUMPH-1-OSA and about 25 events per hour in TRIUMPH-2-OSA.

Clinically meaningful improvements were common. Among participants receiving retatrutide 9 mg or 12 mg, approximately 39% to 52% achieved OSA remission or mild OSA without excessive daytime sleepiness, compared with about 13% of participants receiving placebo. More than half of participants receiving the higher retatrutide doses achieved at least a 50% reduction in AHI.

Weight loss paralleled improvements in OSA severity. Participants receiving retatrutide 9 mg or 12 mg lost approximately 18% to 22% of body weight over 80 weeks, compared with about 5% with placebo. Gastrointestinal adverse events, including diarrhea, nausea, and constipation, were the most common side effects and were generally mild to moderate.

Source: Grunstein RR, et al. (2026 Oct 20) N Engl J Med. Retatrutide Once Weekly for Treatment of Obstructive Sleep Apnea. New England Journal of Medicine